U.S. probes how pharmacies set drug prices as costs rise

The U.S. Federal Trade Commission has opened a probe into how big pharmacy benefit managers like CVS Caremark affect pricing and patients' access to prescription drugs at a time when costs of some medicines, even older ones like insulin, have skyrocketed, the agency said on Tuesday.


As part of the probe, the FTC is sending demands for information to CVS Health Corp's (CVS.N) Caremark, Humana Inc (HUM.N), Cigna Corp's (CI.N) Express Scripts and UnitedHealth Group's (UNH.N) OptumRx, among others.


Read the full story >